精液中高浓度雷替拉韦：EASIER-ANRS 138 试验的亚研究结果。
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
机构信息
Department of Clinical Pharmacy, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris, 78 Rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
Abstract
Raltegravir concentrations and human immunodeficiency virus type 1 (HIV-1) RNA levels in semen samples from 10 treatment-experienced HIV-1-infected patients were measured after 24 weeks of raltegravir-based highly active antiretroviral therapy (HAART). Semen and plasma HIV-1 RNA levels were below 100 copies/ml and 50 copies/ml, respectively, in all samples. The median raltegravir concentrations in semen samples (n=10) and in plasma samples (n=9) drawn simultaneously were 345 (range, 83 to 707) ng/ml and 206 (range, 106 to 986) ng/ml, respectively. The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment.
摘要
在接受拉替拉韦为基础的高效抗逆转录病毒治疗（HAART） 24 周后，检测了 10 名治疗经验丰富的 HIV-1 感染患者的精液样本中的拉替拉韦浓度和人类免疫缺陷病毒 1（HIV-1）RNA 水平。所有样本中的精液和血浆 HIV-1 RNA 水平均低于 100 拷贝/ml 和 50 拷贝/ml。同时采集的 10 份精液样本（n=10）和 9 份血浆样本（n=9）中拉替拉韦的中位数浓度分别为 345（范围，83 至 707）ng/ml 和 206（范围，106 至 986）ng/ml。拉替拉韦浓度的精液与血浆比值中位数为 1.42（范围，0.52 至 6.66），表明拉替拉韦在精液中具有良好的药物穿透性，但存在变异性。
相似文献
1
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
2
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.
3
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.
4
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e58-60. doi: 10.1097/QAI.0b013e31827a0d71.
5
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321.
6
Pharmacokinetics of raltegravir in the semen of HIV-infected men.
Antivir Ther. 2014;19(6):607-11. doi: 10.3851/IMP2750. Epub 2014 Feb 12.
7
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275.
8
Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.
J Clin Pharmacol. 2012 Mar;52(3):440-5. doi: 10.1177/0091270010395939. Epub 2011 Mar 7.
9
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
Antimicrob Agents Chemother. 2011 Jun;55(6):3018-21. doi: 10.1128/AAC.01460-10. Epub 2011 Mar 28.
10
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.
引用本文的文献
1
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21.
2
Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.
J Int AIDS Soc. 2015 May 7;18(1):19470. doi: 10.7448/IAS.18.1.19470. eCollection 2015.
3
Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Antimicrob Agents Chemother. 2015 May;59(5):2572-82. doi: 10.1128/AAC.04594-14. Epub 2015 Feb 17.
4
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.
Clin Pharmacokinet. 2014 Jul;53(7):611-24. doi: 10.1007/s40262-014-0148-z.
5
Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.
Antimicrob Agents Chemother. 2014 Jun;58(6):3360-5. doi: 10.1128/AAC.02757-13. Epub 2014 Mar 31.
6
Characterization of binding of raltegravir to plasma proteins.
Antimicrob Agents Chemother. 2013 Oct;57(10):5147-50. doi: 10.1128/AAC.00625-13. Epub 2013 Jul 15.
7
Antiretroviral bioanalysis methods of tissues and body biofluids.
Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319.
8
The use of preexposure treatments for HIV prophylaxis.
HIV AIDS (Auckl). 2012;4:17-28. doi: 10.2147/HIV.S25082. Epub 2012 Feb 3.
9
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
Antimicrob Agents Chemother. 2011 Jun;55(6):3018-21. doi: 10.1128/AAC.01460-10. Epub 2011 Mar 28.
10
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.
Antimicrob Agents Chemother. 2011 Feb;55(2):879-87. doi: 10.1128/AAC.00623-10. Epub 2010 Nov 15.
本文引用的文献
1
Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 1;878(3-4):456-60. doi: 10.1016/j.jchromb.2009.10.029. Epub 2009 Nov 11.
2
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674.
3
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3.
4
Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
Drugs. 2009 May 29;69(8):1059-75. doi: 10.2165/00003495-200969080-00007.
5
Raltegravir with optimized background therapy for resistant HIV-1 infection.
N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.
6
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13.
7
Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment.
Clin Pharmacol Ther. 2008 Mar;83(3):401-12. doi: 10.1038/sj.clpt.6100342. Epub 2007 Oct 5.
8
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22.
9
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid Commun Mass Spectrom. 2007;21(15):2505-14. doi: 10.1002/rcm.3119.
10
HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.
Retrovirology. 2007 Mar 7;4:17. doi: 10.1186/1742-4690-4-17.
Zotero 插件